About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Antimicrobial Resistance in Cirrhotic Patients | Clinical Trials | Clareo Health

Back to clinical trial search

UNKNOWNNCT04915573

Antimicrobial Resistance in Cirrhotic Patients

Cirrhotic patients are more vulnerable to bacterial infection, and infection is one of the most common causes of acute liver disease decompensation.

Lead sponsor: Mansoura University•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Noha Mansour, Ph.D

CONTACT

0020403315352 dr.nohamansour@gmail.com

Sponsors

Lead Sponsor

Mansoura University

Collaborators

Tanta University

Cirrhotic patients are more vulnerable to bacterial infection which is a common cause of acute liver disease decompensation. The aim of this study will characterize the antimicrobial resistance and distribution of bacteria isolated from chronic hepatic patients with pulmonary infections, as well as to evaluate the antimicrobial susceptibility of bacteria isolated from sputum.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1\. Adults' older than 18 years with clinical evidence of liver disease

Exclusion Criteria

•1. Pregnancy
•2. Intensive care unite stay of more than 24 hours
•3. Malignancy
•4. Organ transplantation
•5. Acquired immune deficiency syndrome

Related studies

Microplastics, Cirrhosis and Portal Hypertension

NCT07280390 · Cirrhosis, Microplastics, and more

Muscle Mass Via UltraSound in Cirrhosis (MMUSCLE)

NCT06345547 · Sarcopenia, Cirrhosis, and more

RECRUITINGPhase 1

The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.

NCT07069725 · Liver Fibrosis, Hepatic Cirrhosis

Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Placement

NCT07439939 · Liver Cirrhosis, Portal Hypertension

CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome

NCT05623150 · Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 10, 2021Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment100

Start dateJun 2021

Last updatedJun 10, 2021

Condition

Locations shown

Tanta University Hospitals

Tanta

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 10, 2021Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions